

52
21. (Thrice Amended) A method for systemic administration of a biologically active polypeptide, comprising providing the composition of claim 1; and causing said patient to inhale said composition from a dry powder inhaler device.

53
30. (Twice Amended) The method of claim 29 wherein the surfactant compound is sodium caprate.

54
56. (Twice Amended) The method of claim 21, wherein said surfactant compound is an alkyl glycoside, a cyclodextrin or derivative thereof, or a phospholipid.

55
59. (Twice Amended) The method of claim 21, wherein said surfactant compound is a bile salt.

56
71. (Amended) The composition of claim 70, wherein said surfactant is a bile salt, an alkyl glycoside, a cyclodextrin or derivative thereof, or a phospholipid.

57
89. (Twice Amended) The dry powder inhaler device of claim 78, wherein said surfactant compound is an alkyl glycoside, a cyclodextrin or derivative thereof, or a phospholipid.

58
94. (Twice Amended) The dry powder inhaler device of claim 78, wherein said surfactant compound is a bile salt. --